Efficient Biological Drug Development Workflows: Lead Candidate to Drug Substance

Discover how to support a faster critical development path and reduce timelines to manufacture of drug substance and product for clinical trials with strategies for maximizing the overlap of activities during process development and manufacture, keeping DC selection options open for longer to generate better data with the aim of minimizing risk.

The discussion explores how the use of small-scale, analogous early material production from stable CHO pools can be employed to unearth potential issues in biological products allowing for better decisions during DC selection and informing process design and control strategies.